FORTIFY Blend (Thymosin Alpha-1 / BPC-157 / KPV / LL-37): What It Is, Where to Get It Prescribed, and What It Costs

FORTIFY is not a single molecule. It is four independently studied peptides — thymosin alpha-1, BPC-157, KPV and LL-37 — dissolved together in one sterile multi-dose vial by a compounding pharmacy. Thymosin alpha-1 and LL-37 are immune peptides; BPC-157 and KPV are the gut-lining and inflammation components. Each has its own research literature, its own described mechanism and its own regulatory file at the FDA. The name is a brand name for the combination; it does not appear in any journal. "Does FORTIFY work" has to be broken into four questions, because the combination itself has never been studied as a combination.

The rationale prescribers give is that "getting sick often" and "recovering slowly" are rarely one problem: immune recognition may be sluggish, the gut lining — where a large share of immune tissue sits — may be inflamed, and inflammation that never resolves keeps the whole system busy. Thymosin alpha-1 is the component described as sharpening immune recognition, LL-37 the body's own first-line antimicrobial, BPC-157 the gut-lining component and KPV the inflammation brake.

The proportions are worth noticing. Thymosin alpha-1 and BPC-157 are 5 mg each of the 13 mg in the vial; KPV is 2 mg and LL-37 is 1 mg. The ratio is fixed by the pharmacy's formulation and cannot be adjusted per component, which is the genuine trade-off of any blend.

It is not an antibiotic. LL-37 is described as antimicrobial in cell studies, but an infection that needs treating is a physician's decision about actual antibiotics or antivirals. It is not a vaccine, not an immunosuppressant, and not a treatment for an autoimmune disease, which is why autoimmune conditions are on the discuss-first list below. It is not a hormone, a steroid or a growth-hormone secretagogue. And thymosin alpha-1 is not thymosin beta-4 or its fragment TB-500, despite the shared name.

Thymosin alpha-1 is a 28-amino-acid peptide the body cuts out of a larger precursor, prothymosin alpha, first isolated from a calf thymus preparation in the 1970s. The thymus — where T cells mature — is the whole story: everything studied since is about what it does to immune cells.

The most-cited mechanism, summarised in a 2020 review in the World Journal of Virology, is action on Toll-like receptors, particularly TLR9 and TLR2, on dendritic cells, the cells that decide what the rest of the immune system responds to. Mouse and cell work describe increased antigen presentation, maturation of immature T cells into functional CD4 and CD8 populations, and increased natural killer cell activity. The direction is described as regulatory rather than purely stimulating: in mouse work it pushes the response toward tolerance rather than inflammation. A fuller treatment is on the thymosin alpha-1 page.

LL-37 is a 37-amino-acid peptide the body cuts from a precursor protein called hCAP18. It is the only cathelicidin humans make, and a 2006 review in Biochimica et Biophysica Acta covers its biology. It is produced by neutrophils and by the epithelial cells of skin, gut and airways — the surfaces that meet microbes first — and released in larger amounts when those surfaces are injured or infected.

Two kinds of activity are described. The first is direct antimicrobial action: LL-37 inserts into and disrupts bacterial membranes, with activity reported against Gram-positive and Gram-negative bacteria, some fungi and some enveloped viruses in cell and animal work. The second is immune signalling: recruiting neutrophils, monocytes and T cells, neutralising bacterial lipopolysaccharide, and, in wound models, promoting keratinocyte migration and new blood-vessel growth. One point of precision: the same review notes that at high concentrations LL-37 is cytotoxic to human cells as well as microbial ones.

BPC-157 is a fifteen-amino-acid partial sequence of a protein originally isolated from human gastric juice, and its largest body of research concerns protection of the gastrointestinal lining in animal models — against NSAID- and alcohol-induced damage, and in inflammatory bowel models. That gut literature is why it is in an immune blend: in the clinical rationale, an inflamed gut lining is a chronic drain on immune resources.

Separately, animal work describes it activating the VEGFR2 receptor and nitric-oxide signalling, the axis the body uses to grow new blood vessels into healing tissue. A 2011 paper in the Journal of Applied Physiology reported tendon outgrowth, cell survival and cell migration through the FAK–paxillin pathway in cultured tendon fibroblasts, and a 2014 paper in Molecules reported increased growth hormone receptor expression in those cells — more responsiveness to growth hormone already present, not more growth hormone. A fuller treatment is on the BPC-157 page.

KPV is the last three amino acids — lysine, proline, valine — of alpha-melanocyte-stimulating hormone. Alpha-MSH drives pigmentation and has anti-inflammatory effects; the isolated tripeptide is reported to keep the second and lose the first, which is why KPV does not darken skin. Cell and animal studies describe it interfering with NF-kB signalling and reducing pro-inflammatory cytokine output. A 2008 paper in Gastroenterology reported that it is taken up into intestinal cells by the PepT1 transporter and reduced inflammation in mouse colitis models, which is the study behind its pairing with BPC-157 here. A fuller treatment is on the KPV page.

The map below is the clinical rationale for the blend. It is a rationale, not a finding — no study has confirmed that the four act together when injected together.

This rests on thymosin alpha-1, the one component in FORTIFY with a real human trial record. Thymalfasin, the synthetic version, has been sold outside the United States since the 1990s and is approved in a number of countries, mainly for chronic hepatitis B and as a vaccine adjuvant. A 2026 Cochrane review pooled ten randomised trials and 1,349 participants with chronic hepatitis B and reported that thymosin alpha-1 may reduce all-cause mortality and serious adverse events, but graded the certainty as very low for almost every outcome: consistent signals across small trials, not settled proof.

In sepsis, two randomised trials in China tell a two-part story. The 2013 ETASS trial in Critical Care randomised 361 patients with severe sepsis and reported 28-day mortality of 26.0 percent with thymosin alpha-1 against 35.0 percent with conventional care, a difference of marginal significance. The follow-up, TESTS, published in the BMJ in 2025, was a double-blind, placebo-controlled phase 3 trial of 1,106 adults: 28-day mortality was 23.4 percent against 24.1 percent, and the trial found no clear evidence that thymosin alpha-1 reduces mortality. It is the largest and best-designed trial of any FORTIFY component in any indication, and its primary result was negative.

This rests on BPC-157 and KPV. BPC-157's original and largest literature is gastrointestinal: animal work describing protection against NSAID- and alcohol-induced gastric damage and improvement in inflammatory bowel models, plus early-phase human work for inflammatory bowel indications. KPV's evidence is animal and cell work in models of gut and skin inflammation; there is no human trial of KPV for any indication.

This rests on LL-37, and the human data here is a specific kind. Two randomised, placebo-controlled trials of topical LL-37 on hard-to-heal venous leg ulcers have been published in Wound Repair and Regeneration. The 2014 first-in-man trial of 34 patients reported faster healing at the two lower concentrations tested and no difference from placebo at the highest. The 2021 phase IIb trial of 148 patients found no significant improvement across the whole study population, with a post hoc signal in the subgroup with large ulcers. Everything else is cell and animal work. There are no human trials of injectable LL-37.

This is the honest part, and the part worth understanding before starting.

There are no randomised controlled trials of FORTIFY, or of any four-peptide combination of these components, in humans. The blend has never been studied as a blend. Evidence is per component, and it is uneven:

• Thymosin alpha-1 has randomised controlled trials spanning more than thirty years — chronic hepatitis B, hepatitis C, sepsis, melanoma and vaccine response — including a 1,106-patient phase 3 sepsis trial. That is far more human evidence than exists for almost any compounded peptide. None of it was generated in otherwise healthy adults who get sick often; that use rests on clinical judgement.
• BPC-157 has early-phase human work for inflammatory bowel indications. There are no large randomised controlled trials in humans.
• KPV has no human trials of any kind.
• LL-37 has two randomised trials of topical application to leg ulcers, with mixed results, and none of the injectable form, which is the form in this vial.

The accurate framing is "one component with human trials in sick populations, three described in preclinical research, all used clinically," not "proven in people."

• That four peptides together do more than any one alone. No study has compared the blend with its components.
• A benefit in healthy adults, for frequent colds, slow recovery or general immune support. That trial has not been run for any component.
• An effect size or a timeline in humans. Timelines given by prescribers are clinical experience, not trial endpoints.
• Long-term safety over years of continuous use, which is part of why a physician reviews each refill.
• Efficacy for any condition as an FDA-approved treatment. Neither FORTIFY nor any component is approved for anything in the United States.

Thymosin alpha-1 was among the peptides the FDA placed in Category 2 of its interim 503A bulk drug substances list in 2023, the category for substances the agency considers to raise significant safety concerns. In September 2024 the FDA removed several substances from Category 2 after their nominations were withdrawn and announced it would take thymosin alpha-1 to its Pharmacy Compounding Advisory Committee on 4 December 2024.

On 4 December 2024 that committee voted 4 in favour and 17 against adding thymosin alpha-1 (free base) to the 503A Bulks List, and 4 to 17 against thymosin alpha-1 acetate. The uses reviewed included hepatitis B and C, HIV, COVID-19, depressed vaccine response, several cancers and sepsis; members who voted no said there was no compelling evidence of effectiveness and safety for those uses. That vote is a recommendation, not a rule. On the FDA's interim list updated 14 May 2026, thymosin alpha-1 does not appear in Category 1, 2 or 3, and the FDA has not issued a final determination either way. It is not on the slate announced for early 2027.

Cathelicidin LL-37 sat in Category 2 from 2023. On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2, effective about a week later, and LL-37 was among them, alongside BPC-157 and KPV. Removal lifts the safety-risk designation; it does not, by itself, place a substance on the positive list. LL-37 was not reviewed at the July 2026 meeting. The FDA has said the committee will consider it, along with GHK-Cu and three others, at a meeting to be held before the end of February 2027.

Both left Category 2 in the same April 2026 action. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8–6, with one abstention in each case, to recommend adding BPC-157 and KPV — each as the free base and the acetate — to the 503A Bulks List. FDA's own scientists had recommended against inclusion, citing insufficient safety, efficacy and characterisation data; the committee voted the other way. The FDA issues its own determination through rulemaking, and that determination is still pending as of September 2026.

None of the four components is currently in Category 2 or otherwise restricted; on the interim list updated 14 May 2026, none appears in Category 1, 2 or 3. Two have been recommended for the positive list and await final FDA action, one is scheduled for review, and one received a negative advisory recommendation in 2024 that the FDA has not acted on. All four remain legal to prescribe and compound. None is an FDA-approved drug product, and compounded medications never are — they are prepared by a licensed pharmacy to a physician's prescription, not approved as manufactured products.

Most people notice little or nothing. Injection-site tenderness is the most commonly reported observation. Some describe an unsettled gut feeling calmer, which prescribers attribute to the BPC-157 and KPV components; noticing nothing in this window is normal.

This is the window one vial covers on a weekday schedule. Where prescribers describe change here, it is usually digestive — less bloating, more predictable bowel habit — rather than anything a person would call "immunity." Immune change is not something you feel week to week.

Whether someone gets sick less often can only be judged over a season. Prescribers who use FORTIFY for frequent infections describe the honest measure as the next three months against the previous three: fewer episodes, or shorter ones, where it happens. That is a clinical impression, confounded by everything else that changes with the seasons, and it typically takes more than one vial to reach.

There is no withdrawal and no rebound described for any component. Whether any benefit persists is the same question that applies to any immune intervention.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication. Because the four are in fixed proportion, every dose delivers the same split: 0.25 mg thymosin alpha-1, 0.25 mg BPC-157, 0.1 mg KPV and 0.05 mg LL-37; you cannot take more of one and less of another.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. There is no "near the problem" logic with FORTIFY: the mechanisms described are systemic, so the site is a matter of comfort and rotation.

20 doses at five per week is four weeks of weekday dosing, which is why refills run on a 28-day cycle. Weekends off is part of the schedule, not a missed dose. One vial per fill, always — not a stockpile. FORTIFY is a vial-and-syringe product only; there is no pepti Pen cartridge for this blend.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating is on the label; a four-peptide vial is not something to keep past it.

Thymosin alpha-1 on its own is the single component with human randomised trials, supplied at 10 mg per vial against the 5 mg in FORTIFY, and available as a pepti Pen, which FORTIFY is not. If the goal is immune modulation alone, the single agent is the more targeted prescription. FORTIFY makes sense when the physician also wants the gut-lining and inflammation components in the same injection.

Both contain BPC-157 and KPV. KLOW pairs them with GHK-Cu and TB-500 and is aimed at tissue repair; FORTIFY pairs them with thymosin alpha-1 and LL-37 and is aimed at immune resilience. A tendon, a wound or skin quality points to KLOW; frequent illness and a gut that never settles points to FORTIFY.

The same BPC-157 and KPV base. The ELEVATE blend adds Semax and Selank, the nootropic and anxiolytic peptides, rather than the immune pair. Which pairing fits is a physician's call.